Kidney damage in hypertension disease

Essential hypertension (EH) is the most common cardiovascular disease and the leading cause of chronic kidney disease  (CKD) worldwide. The aim of the study was to investigate the frequency and nature of kidney damage in hypertension. 189  patients (69 men and 120 women) with hypertension (stages I, II, and III) aged 43 years and older were examined. The average age of the patients was 61.2 ± 8.7 years. Clinical and biochemical tests were conducted on all patients, including red blood  cell indices, C-reactive protein (CRP), lipid profile, fibrinogen, electrolytes, glucose, uric acid, creatinine, and cystatin C. The  duration of hypertension was also recorded for each patient. Kidney function was assessed using serum creatinine (CKD-EPI)  and cystatin C (F. Houcke). Patients were categorized according to the degree of decrease in glomerular filtration rate (GFR)  based on the recommendations of the Russian Nephrology Society. Patients with kidney damage were divided into two groups:  Group 1 consisted of patients with hypertension without signs of CKD (GFR calculated by cystatin C ≥ 60 ml/min), while  Group 2 consisted of patients with hypertension complicated by CKD. The results showed that hypertension was accompanied  by target organ damage in 70.8% of cases. The prevalence of CKD among patients with hypertension was 28.5%. Proteinuria  was mainly detected in patients with renal insufficiency. The frequency of GFR categories according to CKD-EPI and F.  Houcke formulas was as follows: G1 — 54.4% and 13.7% (p < 0.05); G2 — 35.9% and 57.6% (p < 0.05); G3a — 5.2% and  19.5% (p < 0.05); G3b — 3.1% and 5.2% (p < 0.05); G4 — 0.5% and 3.1% (p < 0.05) and G5 — 0.5% and 0.5%, respectively.  There was a strong correlation between GFR and serum creatinine (r = –0.439; p < 0.05) and cystatin C (r = –0.866;  p < 0.0001). Patients in Group 2 (hypertension with kidney damage) had significantly higher levels of CRP, low-density  lipoprotein cholesterol, cystatin C, and longer duration of hypertension, but lower levels of total calcium than patients in  Group 1. In conclusion, CKD was present in 28.5% of patients with hypertension, and proteinuria was mainly detected in  patients with renal insufficiency. Serum cystatin C levels most accurately reflect kidney filtration function.

1. Nanchikeeva M.L., Konechnaya E.Ya., Bulanov M.N. et al. Possibilities of early diagnosis of kidney damage in patients with hypertension. Terapevticheskii arkhiv. 2004;76(9):29–34. (In Russian).

2. Polupanov A.G., Kontsevaya A.V., Khalmatov A.N. et al. Ethnic features of arterial hypertension prevalence in small town and countryside residents of the Kyrgyz Republic: results of the international study INTEREPID. Cardiovascular Therapy and Prevention. 2013;12(6):4–8. (In Russian)]. DOI: 10.15829/1728-8800-2013-6-4-8

3. Kobalava Zh.D., Troitskaya E.A., Kolesnik E.L. New guidelines on management of arterial hypertension: key similarities and diff erences. Rational Pharmacotherapy in Cardiology. 2019;15(1):105–114. (In Russian). DOI: 10.20996/1819-6446-2019-15-1-105-114

4. Uvarovskaia B.V., Mel’nik M.V., Kniazeva S.A. Prevalence of risk factors for arterial hypertension among draft age youth. Systemic Hypertension. 2021;18(2):88–93. (In Russian). DOI: 10.26442/2075082X.2021.2.200845

5. Boytsov S.A., Balanova Yu.A., Shalnova S.A. et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4–14. (In Russian). DOI: 10.15829/1728-8800-2014-4-4-14

6. Kobalava Z.D., Konradi A.O., Nedogoda S.V. et al. Arterial hyper ten sion in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russian). DOI: 10.15829/1560-4071-2020-3-3786

7. Hoek F.J., Kemperman F.A.W., Krediet R.T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular fi ltration rate. Nephrol. Dial. Transplantat. 2003;18(10):2024–31. DOI: 10.1093/ndt/gfg349

8. Moiseev V.C., Mukhin N.A., Smirnov A .V. et al. Cardiovascular risk and chronic kidney disease: cardio-nephroprotection strategies. Russian Journal of Cardiology. 2014;(8):7–37. (In Russian). DOI: 10.15829/1560-4071-2014-8-7-37

9. Fomin V.V., Kotenko O.N. Chronic kidney disease: underestimated risk factors and new clinical guidelines. Consilium Medicum. 2021;23(10):736– 741. (In Russian).

10. Akopyan A.S., Koryakin M.V. Arterial hypertension and kidney disease: doctor’s factor and social factor. Quality Clinical Practice. 2008;(3):116–126. (In Russian).

11. Grinstein Yu.I., Shabalin V.V. Pre-clinical diagnostics of renal lesions in essential hypertension. Cardiovascular Therapy and Prevention. 2003;2(4):50–53. (In Russian).

12. Podzolkov V.I., Bragina A.E., Ishina T.I. et al. Nephroprotective strategy in the treatment of hypertension as a modern general medical problem. Russian Journal of Cardiology. 2018;(12):107–118. (In Russian). DOI: 10.15829/1560-4071-2018-12

13. Podzolkov V.I., Bragina A.E. Chronic kidney disease as a multidisciplinary problem of contemporary medicine. Terapevticheskii arkhiv. 2018;90(6):121– 129. (In Russian). DOI: 10.26442/terarkh2018906121-129

14. Murkamilov I.T., Aitbaev K.A., Fomin V.V., Murkamilova Zh.A. Cystatin C as a marker of chronic kidney disease. Therapy. 2019;5(4):57–62. (In Russian)]. DOI: 10.18565/therapy.2019.4.57-62

15. Bobkova I.N., Shestakova M.V., Schukina A.A. Podocyte damage in diabetes mellitus. Diabetes mellitus. 2014;3:39–50. (In Russian).

16. Shestakova M.V., Shamkhalova M.S., Yarek-Martynova I.Y. et al. Diabetes mellitus and chronic kidney disease: achievements, unresolved problems, and prospects for therapy. Diabetes mellitus. 2011;14(1):81–88. (In Russian). DOI: 10.14341/2072-0351-6254

17. Mukhin N.A., Kozlovskaya L.V., Fomin V.V. et al. Biomarkers of kidney damage in hypertensive patients with hyperuricemia: a personalized approach to assessing prognosis. Clinical Nephrology. 2014;4:16–20. (In Russian).

18. Clinical guidelines. Chronic kidney disease (CKD). Nephrology. 2021;25(5):10–82. (In Russian).

19. Bobkova I.N., Kozlovskaya L.V., Tsygin A.N., Shilov E.M. Clinical practice guideline for diagnostics and treatment of focal segmental glomerulosclerosis. Nephrology (Saint-Petersburg). 2015;19(1):78– 85. (In Russian). DOI: 10.24884/1561-6274-2015-19-1-56-61

20. Bobkova I.N., Gussaova S.S., Stavrovskaya E.V. Kidney damage in obesity: variants of the course, mechanisms of development. Therapy. 2019;5(6):87–93. (In Russian).

21. Chebotareva N.V., Bobkova I.N., Kozlovskaya L.V. et al. Urinary markers of podocyte dysfunction in assessing the prognosis of chronic glomerulonephritis. Modern medical science. 2012;1:81–92. (In Russian).

22. Shcherbak A.V., Kozlovskaya L.V., Bobkova I.N. et al. Hyperuricemia and the problem of chronic kidney disease. Therapeutic archive. 2013;85(6):100–104. (In Russian).

23. Bobkova I.N., Shchukina A.A., Shestakova M.V. Assessment of nephrin and podocin levels in the urine of patients with diabetes mellitus. Nephrology (SaintPetersburg). 2017;21(2):33–40. (In Russian). DOI: 10.24884/1561-6274-2017-21-2-33-40

24. Сlinical signifi cance of nephrin and podocin urinary excretion in patients with diabetes mellitus. Bobkova I., Shchukina A., Shestakova M. Clin. Pharmacol. Ther. 2017;26(5):31–36. (In Russian).

25. Kolomyitseva M.N., Gasanov M.Z., Batyu shin M.M. Contribution of systemic infl ammation to the development of vascular remodeling in patients with chronic kidney disease and sarcopenia. Therapy. 2021;7(5):39–46. (In Russian). DOI: 10.18565/therapy.2021.5.39-46.

26. Statsenko M.E., Turkinа S.V., Tyshchenko I.A. et al. Visceral obesityas a risk marker of multiorgan damage. Bulletin of the Volgograd State Medical University. 2017;1(61):10–15. (In Russian).